Review top news and interview highlights from the week ending June 10, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted in favor of the benefits of bluebird bio's eli-cel in patients with cerebral andrenoleukodystrophy despite substantial safety concerns.
The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed positive data seen with tisa-cel, liso-cel, ide-cel, cilta-cel, and brexu-cel.
Caribou Biosciences’ CB-010, an allogeneic chimeric antigen receptor (CAR) T cell therapy, has demonstrated efficacy in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) with a 100% complete responses (CR) rate.
The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.
Melissa Alsina, MD, gave a talk on novel CAR therapies, targets, and approaches at the 2022 ASCO meeting.
Understanding Disease Pathobiology Will be Key to Developing Cell Therapies for Autoimmune Disease
March 26th 2024Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center discussed the importance of further research into the root cause of MS and other autoimmune diseases.